[{"orgOrder":0,"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Human Alpha 1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Kamada","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Inhaler","sponsorNew":"Kamada \/ Takeda","highestDevelopmentStatusID":"10","companyTruncated":"Kamada \/ Takeda"}]

Find Clinical Drug Pipeline Developments & Deals for Human Alpha 1 Proteinase Inhibitor

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Following the completion of the transition of GLASSIA manufacturing, Kamada will transfer the product’s us biologics license application (BLA) to takeda.

                          Brand Name : Glassia

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 07, 2021

                          Lead Product(s) : Human Alpha 1 Proteinase Inhibitor

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Takeda Pharmaceutical

                          Deal Size : $7.0 million

                          Deal Type : Licensing Agreement

                          blank